It has been found previously that amilorides act via an allosteric site on the ␣ 2A -adrenergic receptor to strongly inhibit antagonist binding. In this study, allosteric modulation of agonist binding and function at the ␣ 2A -adrenergic receptor was explored. The dissociation rate of the agonist [ 3 H]UK14304 from ␣ 2A -receptors was decreased by the amilorides in a concentration-dependent manner. This contrasts with the increases in 3 H-antagonist dissociation rate found previously. The agonistamiloride analog interaction data could be fitted to equations derived from the ternary complex allosteric model. The calculated log affinities of the amilorides at the [ 3 H]UK14304-occupied receptor increased with the size of the 5-N-alkyl side chain and ranged from 2.4 for amiloride to 4.2 for 5-(N,N-hexamethylene)-amiloride. The calculated negative cooperativities cover a narrow range, in sharp contrast to the broad range found for antagonist-amiloride analog interactions. The effects of the amilorides on the agonist actions of UK14304, epinephrine, and norepinephrine were explored using a [
H-antagonist dissociation rate found previously. The agonistamiloride analog interaction data could be fitted to equations derived from the ternary complex allosteric model. The calculated log affinities of the amilorides at the [ 3 H]UK14304-occupied receptor increased with the size of the 5-N-alkyl side chain and ranged from 2.4 for amiloride to 4.2 for 5-(N,N-hexamethylene)-amiloride. The calculated negative cooperativities cover a narrow range, in sharp contrast to the broad range found for antagonist-amiloride analog interactions. The effects of the amilorides on the agonist actions of UK14304, epinephrine, and norepinephrine were explored using a [
35 S]GTP␥S functional assay, and the parameters calculated for the cooperativities and affinities of the UK14304-amiloride analog interactions, using the equation derived from the ternary complex allosteric model, were in good agreement with those derived from the kinetic studies. Therefore both the binding and functional data provide further support for the existence of a well defined allosteric site on the human ␣ 2A -adrenergic receptor. The binding mode of the amilorides at the agonist-occupied and antagonist-occupied receptor differs markedly but, within each group, the structure of either the agonist or the antagonist examined has only a slight effect on the allosteric interactions.
Currently used drugs that bind to G protein-coupled receptors produce their therapeutic effects either by mimicking (in the case of agonists) or blocking (in the case of antagonists) the action of the endogenous signaling molecule, by competing with it at the same primary binding site on the receptor. The effect of such drugs is to either generate continuous stimulation or chronic blockade of receptor function at all the receptor molecules. In certain therapeutic indications, it may be more desirable to have an alternative approach, that of controlling the activity of the endogenous agonist at a given receptor.
This regulation of receptor function can be accomplished if a ligand operates by an allosteric mechanism, i.e., the ligand binds to a different site on the receptor from the endogenous agonist, to modulate agonist binding and function. The simplest scheme is shown in Fig. 1 (solid lines) . The two parameters that describe the action of an allosteric agent X are its affinity for the receptor (K X ) and its cooperativity (␣) with a primary binding site ligand L, which may be the endogenous agonist. The cooperativity factor ␣ can be greater than, less than, or, in a special case, equal to 1: this corresponds to positive, negative, or neutral cooperative interactions, respectively.
One example of such a potential therapeutic area is the use of an allosteric muscarinic enhancer (␣ Ͼ 1 with L being acetylcholine) in the early stages of Alzheimer's disease, to alleviate the cognitive deficits that are thought to be caused by the localized degeneration of cholinergic nerve terminals and the associated acetylcholine deficit (Giacobini, 1990; Ehlert et al., 1994) . In fact, M 2 muscarinic receptors were the first G protein-coupled receptor at which allosterism was demonstrated, when the antagonism by gallamine of the negative inotropic effect of muscarinic agonists in the heart was investigated (Clark and Mitchelson, 1976) . This work was confirmed and extended by Stockton et al. (1983) . From a therapeutic viewpoint, however, it is necessary to be able to enhance acetylcholine function in a subtype-selective manner, and this has recently been achieved with brucine and related compounds (Birdsall et al., 1997 .
There have been relatively few reports on the detailed characterization of the effects of allosteric ligands on agonist Financial support: R.A.L. is a recipient of a ROPA research grant. A preliminary report of the work described in this manuscript was presented at the XIIIth International Congress of Pharmacology, 1998 (Leppik et al., 1998b). binding (especially kinetics) and function. Outside of the muscarinic area, studies on adenosine receptors have shown that PD81,723 enhances agonist binding and function at the adenosine A 1 receptor as well as modulating agonist kinetics at the receptor-G protein complex (Bruns and Fergus, 1990; Cohen et al., 1994; Musser et al., 1999) .
With adrenergic receptors, it has been demonstrated that amilorides can act allosterically at a single allosteric site on the ␣ 2A -adrenergic receptor, and in a more complex manner at the ␣ 1A -adrenergic receptor, to inhibit antagonist binding (Nunnari et al., 1987; Leppik et al., 1998a Leppik et al., , 2000 . However, there have been no studies of agonist-amiloride interactions. In this paper we present a quantitative investigation of the allosteric interactions of amiloride analogs on agonist binding and function at the ␣ 2A -adrenergic receptor, including the effects of the amilorides on the actions of the endogenous agonists, epinephrine and norepinephrine. Aqueous stock solutions (10 mM) of the amilorides in HEPES buffer were prepared fresh as required, as described previously (Leppik et al., 1998a) . The use of organic solvents to dissolve the amilorides was avoided, because of the previously observed effects of organic solvents on the equilibrium binding of antagonists to the ␣ 2A -adrenergic receptor (Leppik et al., 1998a) .
Experimental Procedures
Cell Culture and Membrane Preparation. The CHO cell line stably expressing the human ␣ 2A -adrenergic receptor (Kurose and Lefkowitz, 1994) was generously provided by Professor Robert J. Lefkowitz (Howard Hughes Medical Institute, Duke University Medical Center, Durham, NC). The cell line was grown in ␣-minimal essential medium supplemented with 10% newborn calf serum, 2 mM L-glutamine, 50 I.U./ml penicillin, and 50 g/ml streptomycin, at 37°C in 5% CO 2 . Membranes were prepared as described previously (Leppik et al., 1998a) . Briefly, near-confluent cells were harvested in cold buffer 1 (20 mM Na-HEPES, pH 7.4, 10 mM EDTA), then homogenized, and centrifuged. The pellet was resuspended in buffer 2 (20 mM Na-HEPES, pH 7.4, 0.1 mM EDTA), recentrifuged, again resuspended in buffer 2, and then stored at Ϫ70°C. Protein concentrations were determined by the method of Bradford (1976) , using bovine serum albumin as the standard.
Radioligand Binding Assays. For competition experiments, membranes (20, 25, or 30 g of protein) were incubated with approximately 6, 0.6, or 0.3 nM [ 3 H]UK14304, respectively, in duplicate, together with increasing concentrations of competing agent, in a final volume of 1 ml of assay buffer (20 mM Na-HEPES, pH 7.4, 100 mM NaCl, 10 mM MgCl 2 ), at 30°C for 120 min. Nonspecific binding was defined as the binding retained on the filter and membranes in the presence of 20 M phentolamine. Bound and free ligand were separated by rapid filtration under vacuum through GF/B glass fiber filters (Whatman, Maidstone, Kent, UK) using a Brandell cell harvester (Semat, St. Albans, Hertfordshire, UK). The filters were washed three times with cold 20 mM sodium phosphate buffer, pH 7.4, and transferred to scintillation vials. Scintillation cocktail (Beckman, Palo Alto, CA) was added, and the filters were soaked overnight and then counted.
In exploratory association experiments, in which sets of tubes containing membranes (20 g) in assay buffer (950 l) were placed in a 30°C bath and then [ 3 H]UK14304 (50 l, 120 nM) was added to individual tubes at varying times, the association of [ 3 H]UK14304 appeared biphasic, with an initial rapid rise, followed by a steady upward rise ("creep") for at least 3 h. A biphasic association was also reported by Neubig et al. (1988) , who demonstrated that the fast component was UK14304 concentration dependent, but the slow component was not. However, if in the association assay the membrane suspension was instead kept on ice, and aliquots (100 l, 20 g membranes) were only added to tubes containing assay buffer (850 l) at 30°C 5 min before the [ 3 H]UK14304 (50 l) addition, the creep was eliminated, with the level of [ 3 H]UK14304 bound remaining constant for between 1 and 6 h, at all the concentrations examined (0.1-10 nM). This would suggest that components in the system responsible for the generation or maintenance of the high-affinity state of the receptor are unstable at 30°C but are stabilized by UK14304 concentrations as low as 0.1 nM.
Because of this instability, membranes were also kept on ice until exposed to agonist in the dissociation assay protocol developed. Thus, aliquots (100 l) of an ice-cold membrane suspension (25 g) were added at various times to tubes containing [ 3 H]UK14304 (16.7 nM) in assay buffer (150 l) at 30°C, each mixture was left 40 min for equilibration, and then an aliquot (200 l) of this mixture was transferred to a second tube at 30°C containing phentolamine (25 M) in assay buffer (800 l) to commence the measurement of the dissociation. Additions were timed so that the contents of the second set of tubes were filtered at the same time. To determine nonspecific binding at all time points, phentolamine (33 M) was included in a second batch of the tubes containing the radioligand, and then the experiment was repeated. In those experiments in which the effects of the amilorides on the dissociation of [ 3 H]UK14304 were examined, the amilorides were also included in the second set of tubes with the phentolamine. The filtrations and counting were performed as above, except that filters were washed only twice, but with larger volumes of wash buffer, to keep harvesting time to a minimum but nevertheless reduce nonspecific binding. With this protocol, two-site exponential fits of the dissociation data were found to be not significantly better than one-site fits (P Ͼ .1).
[ 35 S]GTP␥S Assays. In each tube of a set of 24 tubes, membranes (10 g) were incubated at 30°C with GDP (1 M), [
35 S]GTP␥S (0.05 nM), a given concentration of the amiloride to be tested (where relevant), and an increasing concentration of agonist in duplicate, in a final volume of 1 ml of assay buffer. Sufficient sets of 24 tubes figure) . In this scheme, the radioligand L and the allosteric agents X and Y bind to the primary and allosteric sites, respectively, on the receptor R. K L , K X , and K Y are the affinity constants for L, X, and Y, respectively, for binding to R, ␣, and ␤ are the cooperativity factors between X or Y, respectively, and L, and k Ϫ1 , k Ϫ2 , and k Ϫ3 are the rate constants for L dissociating from RL, XRL, and YRL, respectively.
(normally five to seven sets) were assayed consecutively, to enable the desired concentration range of the amiloride to be tested to be covered. Where the agonist was either epinephrine or norepinephrine, sodium metabisulfite (1 mM) was also included. Sodium metabisulfite had been found in initial tests to be necessary, to minimize a decrease in the [
35 S]GTP␥S bound at concentrations of epinephrine or norepinephrine over 0.1 mM (data not shown). The time course for each set of 24 tubes was started by the addition of the membrane suspension and terminated by filtration after 60 min, as described above.
Data Analysis. Data were fitted by nonlinear regression analyses, using the Grafit curve-fitting software (Erithacus Software, Staines, Middlesex, UK). This procedure allows the use of two or more independent variables (e.g., time and concentration), which was necessary for many of the analyses reported in this paper.
Competition experiment data were fitted to a one-site equation with a slope factor, as described previously (Leppik et al., 1998a (Neubig et al., 1988, and Results) , a simple affinity constant for UK14304 binding at this receptor could not be derived. Thus, in each set of competition experiments between [ 3 H]UK14304 and the amilorides, a competition experiment versus phentolamine was performed as a control. The calculated log IC 50 from the control experiment and the previously determined log affinity value for phentolamine (7.25; R. Leppik, unpublished data) were used to calculate an apparent log affinity value for the UK14304 at the concentration used, using the Cheng-Prusoff equation (Cheng and Prusoff, 1973) . The IC 50 values for the amilorides were then converted to the log affinity constant log K x using the derived apparent log affinity value for [
3 H]UK14304 in the Cheng-Prusoff correction.
Data from dissociation experiments performed in the absence of added amilorides were fitted to either the single-or the doubleexponential decay equations of the Grafit software. For data obtained from radioligand dissociation experiments performed in the presence of one or two amiloride analogs, the equations used and the method of fitting are as described in a previous study (equation 10 and 9, respectively, Leppik et al., 1998a) .
Data from [ 35 S]GTP␥S assays performed in the absence of amiloride analogs were fitted by the four parameter logistic equations of the Grafit software. Those assays performed in the presence of a range of amiloride analog concentrations were simultaneously fitted by the equation derived in a previous study (equation 37, Lazareno and Birdsall, 1995) . In the fitting of the data, the agonist and amiloride concentrations were independent variables, and the equation was recast in terms of log affinity constant, log EC 50 , log concentrations, and log cooperativity factor (Hulme and Birdsall, 1992) .
For the statistical comparison of the goodness of fit of data to two separate equations, the F test of the Grafit software was used. For statistical comparison of two sets of data, a Student's paired t test was used.
Results

Effect of Amiloride Analogs on the Equilibrium Binding of [ 3 H]UK14304. The data from competition experiments between [
3 H]yohimbine and UK14304 at the human ␣ 2A -adrenergic receptor, permanently expressed in a CHO-K1 cell line (Kurose and Lefkowitz, 1994; Leppik et al., 1998a) , were compatible with the presence of two high-affinity GTP-sensitive agonist sites and one low-affinity GTPinsensitive agonist site, with log affinities of 10. In the dissociation assay protocol developed, the membrane suspension containing the ␣ 2A -adrenergic receptor was kept on ice, and then aliquots were added to tubes containing [ 3 H]UK14304 in assay buffer at 30°C. After 40 min of equilibration, an aliquot of this mixture was transferred to a second tube at 30°C containing phentolamine with or without amiloride analog in assay buffer, to start the dissociation. With this protocol, the dissociation of the [ 3 H]UK14304 from the ␣ 2A -adrenergic receptor was found to be monoexponential in the absence or presence of a given concentration of amiloride analog; a double-exponential equation did not give a significantly better fit of the data (P Ͼ .1). [
3 H]UK14304 alone had a dissociation rate from the ␣ 2A -adrenergic receptor at 30°C of 0.041 Ϯ 0.003 min Ϫ1 (t 1/2 ϭ 17 min; n ϭ 6). When the effects of the amilorides (Fig. 2) on [ 3 H]UK14304 dissociation from the ␣ 2A -adrenergic receptor at 30°C were examined, the data suggested that the amilorides were causing a slight decrease in the [ 3 H]UK14304 dissociation rate. However, only the effect of HMA was large enough to be quantitated. When the HMA data were fitted (Fig. 3) by the equation derived from the ternary complex allosteric model (Fig. 1, solid lines) (Lazareno and Birdsall, 1995) , the parameters obtained (Table 1 ) showed that the [ 3 H]UK14304 dissociation rate from the HMA-occupied receptor was ϳ2.7-fold slower than that from the unoccupied receptor. The log affinity of HMA at the [ was 4.24 (1/␣K X : 58 M). As the log affinity of HMA at the unoccupied ␣ 2A -adrenergic receptor (log K x ) was 6.74 (see above), the difference between these two log affinity values, the observed log cooperativity factor (log␣), was Ϫ2.50 (1/␣ ϭ 320).
Because the other amilorides caused even smaller changes in the [ 3 H]UK14304 dissociation rate, their effects could only be quantitated by their modulation of the HMA effect on [ 3 H]UK14304 dissociation. This was done for amiloride and DMA, the two other amilorides successfully studied in the [ 35 S]GTP␥S assay (below). The data were well fitted (Fig. 4) by the dissociation equation derived from the model that allows competition between two allosteric agents at the allosteric site (Fig. 1) (Leppik et al., 1998a) . Those parameter estimates derived for HMA agreed well with the ones calculated for HMA alone ( Table 1) . As anticipated, the [ 3 H]UK14304 dissociation rates from the amiloride-occupied or DMA-occupied receptors were only slightly decreased compared with the dissociation rate of [ 3 H]UK14304 from the unoccupied receptor, the fold decreases being 1.5 and 1.3, respectively ( Table 1 ). The log affinities of amiloride and DMA at the [ 3 H]UK14304-occupied receptor were calculated to be 2.39 and 3.39 (1/␣K X : 4100 and 410 M), respectively ( Table 1) . Use of the log affinity values for amiloride and DMA at the unoccupied receptor derived above enabled the observed log cooperativities to be calculated as Ϫ2.21 and Ϫ2.10 (1/␣ ϭ 160 and 130), respectively ( Table 1) . The experiments were performed at 30°C, as described in the legend of Fig. 3 . The data from each experiment were fitted to the single-exponential equations derived in a previous study (equations 10 and 9, respectively, Leppik et al., 1998) . k Ϫ1 , k Ϫ2 , and k Ϫ3 are the dissociation constants for the dissociation of [ 3 H]UK14304 from the unoccupied (k Ϫ1 ), HMA-occupied (k Ϫ2 ), or amiloride-or DMA-occupied (k Ϫ3 ) receptors. The log ␣ obs and log ␤ obs are the calculated differences between the log affinity of the amiloride analog at the agonist-occupied receptor (log ␣K X or log ␤K Y ) and the log affinity at the unoccupied receptor (log K X , described in the second paragraph under Results). Values are means Ϯ S.E. of three experiments. 3 H]UK14304 pre-equilibrated at 30°C and then, after 40 min, a portion was transferred to a second tube at 30°C containing phentolamine and various concentrations of HMA to commence the dissociation measurement. Individual data points from one experiment are shown. The data from each experiment were simultaneously fitted to the equation from the allosteric model (Fig. 1, solid lines) (eq. 10, Leppik et al., 1998) , with time and HMA concentration as independent variables. The results are summarized in Table 1 containing the ␣ 2A -adrenergic receptor was examined. Norepinephrine, epinephrine, and UK14304 were found to be full agonists, giving over a 5-fold stimulation over basal (Table 2) , with the order of potency UK14304 Ͼ epinephrine Ͼ norepinephrine. Guanabenz, p-aminoclonidine, and clonidine were found to be partial agonists, giving approximately half-maximal stimulation (Table 2) . Similar results were reported by Jasper et al. (1998) in studies with the human ␣ 2A -adrenergic The experiments were performed as described in the legend to Fig. 3 . Individual data points from one experiment are shown per graph. The lines represent the simultaneous fit of the data to the equation derived from the allosteric model that allows for competition between the allosteric agents at the allosteric site ( Fig. 1) (eq. 9, Leppik et al., 1998) . In the fitting, time, HMA concentration and either amiloride or DMA concentration were independent variables. The arrows show the direction of the effect of amiloride (A) or DMA (B) on the modulation by HMA of the [receptor expressed in an HEK 293 cell line. Oxymetazoline and L(Ϫ)-norephedrine were also tested and were found to be even less efficacious agonists, giving less than a 2-fold stimulation over basal (data not shown). p-Aminoclonidine caused a biphasic stimulation, the level of [
Characterization of Agonist-Stimulated Binding of [
35 S]GTP␥S binding reaching a plateau 2.8 times basal at 10 M and then showing a second rise at higher p-aminoclonidine concentrations. This second rise was not blocked by the antagonist yohimbine (1 M). The p-amino grouping is critical for this second phase, because this second phase is not shown by clonidine. Despite the yohimbine result, the p-aminoclonidine still could be acting via the ␣ 2A -adrenergic receptor, because CHO membranes lacking the ␣ 2A -adrenergic receptor did not display either phase. This phenomenon was not explored further in the current study.
Effect of Amiloride Analogs on the Stimulation of [ 35 S]GTP␥S Binding by Agonists.
All six of the amiloride analogs tested (Fig. 2) caused a concentration-dependent decrease in the potency of norepinephrine to stimulate [ 35 S]GTP␥S binding to CHO membranes containing the ␣ 2A -adrenergic receptor ( Fig. 5 ; not shown). However, above a given concentration, all of the amilorides also caused a decrease in the maximal level of norepinephrine-induced [ 35 S]GTP␥S binding, and in some cases there was also a variation in the level of basal binding at these higher concentrations. Thus, the equation derived by Lazareno and Birdsall (eq. 37, 1995 ) from the allosteric model could only be applied to data derived using amiloride analog concentrations below those concentrations that caused changes in maximal and/or basal levels of [ 35 S]GTP␥S binding. With amiloride and DMA, a decrease in the maximal stimulation of [ 35 S]GTP␥S binding by norepinephrine, epinephrine, or UK14304 was only found at 3 mM amiloride analog concentration. The data obtained with concentrations of amiloride or DMA up to 1 mM were well fitted by the equation from the allosteric model (Lazareno and Birdsall, 1995) , for their effect on either norepinephrine-, epinephrine-, or UK14304-stimulated [
35 S]GTP␥S binding ( Fig. 5 and Table 3 ; not shown). The data were significantly (P Ͻ .05) better fitted by the equation derived from the allosteric model (eq. 37, Lazareno and Birdsall, 1995) than by the equation for the competitive model (eq. 37, b ϭ 0, Lazareno and Birdsall, 1995) . The analyses by the allosteric model give separate estimates of both the log affinity of the amilorides at the unoccupied receptor (log K X ) and the log cooperativity between the amilorides and the agonists (log ␣) (Table 3) , unlike a dissociation assay that gives only estimates of a single combined parameter, the log affinity of the allosteric ligand at the radioligand-occupied receptor (log ␣K X ).
In the case of HMA, decreases in the maximal stimulation of [
35 S]GTP␥S binding by norepinephrine, epinephrine, or UK14304 were found with 0.1 mM HMA. The data obtained with HMA concentrations up to 0.03 mM were well fitted ( Fig. 5 and Table 3 ; not shown) by the equation from the allosteric model. With the other amilorides examined, BZA, MBA, and EPA, there was a decrease in the maximal level of norepinephrine-stimulated [
35 S]GTP␥S binding with 0.1, 0.1, and 1 mM amiloride analog, respectively, together with a decrease (BZA and EPA) or an increase (MBA) in basal binding at these amiloride analog concentrations. Below these concentration limits, it was found that the concentration ranges over which these amilorides were causing a decrease in agonist potency were too restricted to enable the data to be fitted other than by an equation derived from a competitive model. The only parameter estimates that could be derived for these three amilorides from the [
35 S]GTP␥S assay were their log affinities at the unoccupied receptor, and these estimates are within 0.2 log unit of the corresponding corrected affinity values estimated from competition studies versus [
3 H]UK14304 and [ 3 H]yohimbine (Leppik et al., 1998a ; data not shown). This competitive-like behavior is compatible with allosterism. The allosteric ternary complex model (Fig. 1) , when there is negative cooperativity, behaves as a competitive model until sufficiently high concentrations of X and L are present to enable a significant level of the ternary complex, X.R.L, to be formed.
Discussion
Previous studies have shown that the ␣ 2A -adrenergic receptor possesses a well defined allosteric site, at which amilorides can act to modulate antagonist binding at the primary binding site (Leppik et al., 1998a) . This differs from the situation found for the ␣ 1A -adrenergic receptor, for which the data are compatible with two, but not one, allosteric sites at which amilorides can bind and modulate antagonist binding (Leppik et al., 2000) . In this paper, we quantitate the behavior of amilorides, acting via the allosteric site on the ␣ 2A -adrenergic receptor, to modulate agonist binding and function.
Initially, competition studies were carried out between the potent, ␣ 2 -selective agonist [ 3 H]UK14304 and the amilorides at the ␣ 2A -adrenergic receptor. The affinities calculated for the amilorides at the unoccupied receptor are in good agreement with those previously determined from competition studies versus the antagonist [ 3 H]yohimbine (Leppik et al., 1998a) . This argues that the amilorides do not have additional potent effects on G proteins that disrupt receptor-G In kinetic studies, the amilorides examined caused modest concentration-dependent decreases in the dissociation rate of the [ 3 H]UK14304 from the ␣ 2A -adrenergic receptor. The decreases were so slight that only HMA showed a large enough effect to enable the dissociation data to be fitted by the equation derived from the ternary complex allosteric model (Fig. 3) . For the other amilorides, the parameters defining the allosteric interaction could only be derived by analyzing the effect on the [ 3 H]UK14304 dissociation rate of the competition between each amiloride and HMA at the allosteric site. This was done for both amiloride and DMA, the two other amilorides successfully studied in the [
35 S]GTP␥S assay, and the data obtained could be well fitted (Fig. 4) by the relevant equation (Leppik et al., 1998a) . The reversal of the kinetic effects of HMA by amiloride and DMA, in a manner compatible with the allosteric model, argues against their interactions being nonspecific in nature.
The [ 3 H]UK14304 dissociation rates from the amiloride-, DMA-, or HMA-occupied receptors were estimated to be 1.5-, 1.3-, or 2.7-fold slower, respectively, than from the unoccupied receptor (Table 1) . These slight decreases are in contrast to the larger increases caused by the amiloride analogs (especially HMA) on antagonist dissociation rates (Leppik et al., 1998a) . For example, the [ 3 H]yohimbine dissociation rates from the amiloride-, DMA-, or HMA-occupied receptors were 2-, 5-, and 140-fold faster, respectively, than that from the unoccupied receptor (Leppik et al., 1998a) .
From the analysis of the kinetic data, the calculated affinities of the amilorides at the [ 3 H]UK14304-occupied receptor were found to correlate with the size of the 5-N-alkyl side chain. Amiloride, with only a 5-amino function (Fig. 2) , has a log affinity of 2.38 (1/␣K X : 4 mM), whereas DMA, which has a 5-dimethylamino function, has a log affinity of 3.39 (1/␣K X : 400 M), and HMA, with a hexamethylene ring on the 5-amino function, has a log affinity of 4.24 (1/␣K X : 60 M; Table 1 ). These values parallel the rank order of affinities of the amilorides for the unoccupied ␣ 2A -adrenergic receptor but are ϳ100-fold weaker. The differences between the log affinities at the [ 3 H]UK14304-occupied and unoccupied receptors, the log cooperativities, range from Ϫ2.2 for amiloride to Ϫ2.5 for HMA (Table 1) .
The values in Table 1 contrast with those found for the amilorides at antagonist-occupied ␣ 2A -adrenergic receptors (Leppik et al., 1998a ). There, not only do the log affinities not correlate with the size of the 5-N-alkyl side chain but they also are found in a narrow range (2.1-2.5), whereas the observed log cooperativities vary considerably (Ϫ2.4 to Ϫ4.2). In the current study, it is the log affinities at the [ 3 H]UK14304-occupied receptor that vary (2.4 -4.2), whereas the log cooperativities are approximately constant.
The kinetic data suggest that the apparent association rate constants of [ 3 H]UK14304 for the receptor occupied by one of the amilorides (␣.K L .[k Ϫ2 or k Ϫ3 ]) varies only over a narrow range, and is ϳ500-fold slower than the association rate constant of [ 3 H]UK14304 for the unliganded receptor (K L .k Ϫ1 ); i.e., (␣.[k Ϫ2 or k Ϫ3 ])/k Ϫ1 ϭ 0.0012 to 0.0061 (Table  1 ). The magnitude of the decrease of the association rate Table 3. original allosteric ligands exhibited strong negative cooperativity. The finding of only 60-fold negative cooperativity between amiloride and the endogenous ligand norepinephrine at the ␣ 2A -adrenergic receptor means that it is possible that allosteric enhancers at this receptor also await discovery.
It has been demonstrated recently that the benzodiazepines, lorazepam and midazolam, can act as weak agonists of very low intrinsic activity at the three ␣ 1 -adrenergic receptor subtypes and that they increase the maximal inositol phosphate response of phenylephrine, clonidine, or epinephrine at one or more subtypes (Waugh et al., 1999) . These actions are ascribed to an allosteric mechanism. However, the data from the binding and functional studies are not compatible with the predictions of the ternary complex allosteric model (Fig. 1 ) and suggest that a more complex mechanism is involved. Thus, the work reported here is the first clear demonstration of allosteric modulation of both agonist binding and function at an adrenergic receptor subtype.
